Atrium Health Neurosciences Institute Charlotte, a facility of Carolinas Medical Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khella, Sami
NCT06517758: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Recruiting
3
146
Europe, Japan, US, RoW
Iptacopan, Matching Placebo
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
12/26
05/32
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
EDONA, NCT05311488: Early Detection of Neuropathy in ATTRv

Active, not recruiting
N/A
47
US
neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
University of Pennsylvania, Ionis Pharmaceuticals, Inc., AstraZeneca
Hereditary Amyloidosis, Transthyretin-Related
06/25
02/29
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Active, not recruiting
N/A
413
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25
Vo, Mary
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khella, Sami
NCT06517758: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Recruiting
3
146
Europe, Japan, US, RoW
Iptacopan, Matching Placebo
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
12/26
05/32
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29
EDONA, NCT05311488: Early Detection of Neuropathy in ATTRv

Active, not recruiting
N/A
47
US
neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
University of Pennsylvania, Ionis Pharmaceuticals, Inc., AstraZeneca
Hereditary Amyloidosis, Transthyretin-Related
06/25
02/29
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Active, not recruiting
N/A
413
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25
Vo, Mary
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
335
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
03/29

Download Options